As traditional compound utilization and cost continue to decline, high impact therapeutic categories are emerging to take their place. In 2018, compound kits and combo packs each represented less than 1% of total prescriptions and drug costs. However, their presence is of growing concern due to the lack of evidence supporting their use and packaging strategies that are associated with exorbitant pricing. These and other challenges call for careful oversight that includes identification, clinical review and intervention, and/or recommendation of therapeutic alternatives where appropriate to help control inappropriate utilization and spend. Watch the video blog to learn more.
More stories
Business Insurance
In the News
Silica-related lung injuries prompt enforcement, mitigation efforts
Auto Casualty
Article
Building a Resilient Future for the Insurance Industry with DecisionPoint
In today's insurance landscape, the shortage of experienced adjusters is more than just a challenge—it's a turning-point for claims processing exce
Business Insurance
In the News
Presumptions in comp fail to gain traction this year
Workers' Comp
Article
10 Questions Every Injured Employee Should Ask When Taking Opioids
What are the most important things you need to know about your medicines? Make sure you know about each of t
Workers' Comp
Case Study
Transforming a Third Party Administrator’s (TPA) Telephonic Case Management Program
Workers' Comp
Case Study